Head-to-head evidence
Levilimab vs tocilizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: IL-6 receptor · full Rheumatoid Arthritis pipeline
Levilimab
Developed by Biocad
NCT04227366 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 154 patients that measured ACR20 response, a validated rheumatoid arthritis disease-activity measure, at week 12. Levilimab combined with methotrexate produced a much higher response rate than placebo combined with methotrexate (68.6% vs 38.5%).
tocilizumab · Actemra / RoActemra
Marketed by Roche and partners
NCT03155347 · Phase 3 · completed
This randomized, double-blind, active-comparator trial of 340 participants met its primary endpoint: about half of tocilizumab-treated patients achieved an ACR20 response at 24 weeks, compared with a quarter on methotrexate alone, a highly statistically significant difference for both the combination and monotherapy arms.
Next expected readout: August 2028 · NCT05869955 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levilimab's landscape · tocilizumab's landscape